The Advanced Research Projects Agency for Health (ARPA‑H) awarded funding to seven teams to accelerate in‑vivo approaches that program immune cells directly inside the body. The grants target technologies that combine gene editing, mRNA delivery, and novel modalities to teach endogenous immune cells to fight disease without ex vivo manipulation. ARPA‑H emphasized projects that increase manufacturability, enable redosing, and lower cost compared with viral‑vector‑based ex vivo cell therapies. Funded efforts include LNP delivery strategies, selective mRNA expression, and in vivo CAR‑like constructs intended for hematologic cancers and autoimmune indications. The initiative reflects a coordinated federal push to move transformative, scalable cellular therapeutics toward clinical testing and commercialization through targeted funding and engineering milestones.